In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Larimar Therapeutics, Inc.

https://larimartx.com/

Latest From Larimar Therapeutics, Inc.

Nicox’s NCX 470 Hits Phase III Endpoint In Glaucoma But Misses Superiority

NCX 470 demonstrates non-inferiority in intraocular pressure reduction versus latanoprost in the first of two Phase III studies, but does not meet a secondary endpoint that would have shown superiority.

Clinical Trials Business Strategies

Finance Watch: Third Harmonic Launches The Largest IPO In Months

Biopharma stock prices overall are trending down again, but standout firms are raising cash, including the first company to price an IPO over $100m since May, Third Harmonic. Also, Sarepta and Alnylam launched large note offerings, totaling $1bn and $900m, respectively.

Financing Business Strategies

Finance Watch: Sironax, IDRx, OriCell Reveal First VC Mega-Rounds Of August

Private Company Edition: Sironax completed a $200m series B round while IDRx launched with $122m and OriCell raised $120m in series C funds, joining end-of-July $100m-plus fundraiser Carmot Therapeutics, which closed a $160m series D financing. 

Financing StartUps and SMEs

Larimar Secures PRIME Designation In EU For Neurological Disease Drug

The European Medicines Agency has accepted Larimar’s potential treatment for Friedreich’s ataxia onto its PRIME scheme for helping to get medicines for unmet medical needs to patients faster.

Europe Research & Development
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Other Names / Subsidiaries
    • Chondrial Therapeutics, Inc.
    • Zafgen, Inc.
UsernamePublicRestriction

Register